Evidence map›Paper›PMID 26169267›Full record

ArticleInfection and immunity2015

Induction of Multifunctional Broadly Reactive T Cell Responses by a Plasmodium vivax Circumsporozoite Protein Recombinant Chimera.

Monica Cabrera-Mora, Jairo Andres Fonseca, Balwan Singh, Joseli Oliveira-Ferreira, Josué da Costa Lima-Junior, J Mauricio Calvo-Calle, Alberto Moreno

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. A multivalentBioengineering & translational medicine · 2023
    Article
  3. Structural basis ofeLife · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Monica Cabrera-MoraEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Jairo Andres FonsecaEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Balwan SinghEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Joseli Oliveira-FerreiraLaboratory of Immunoparasitology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Josué da Costa Lima-JuniorLaboratory of Immunoparasitology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
J Mauricio Calvo-CalleDepartment of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Alberto MorenoEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, USA alberto.moreno@emory.edu.
Emory University · USFundação Oswaldo Cruz · BRUniversity of Massachusetts Chan Medical School · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 1985 to 2011
$114.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
T cell and transgenic core U19AI109858 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WELSH, RAYMOND M · 2014 to 2018
$11.9M
Optimization of chimeric multi-stage immunogens for malaria vaccine developmentR56AI103382 · NIAID · EMORY UNIVERSITY · PI MORENO, ALBERTO · 2014 to 2014
$844k
Coadministration of capsid modified adenovirus for malaria vaccine developmentR21AI095718 · NIAID · EMORY UNIVERSITY · PI MORENO, ALBERTO · 2012 to 2013
$490k
Chimeric hybrid transmission blocking vaccine for malariaR21AI094402 · NIAID · EMORY UNIVERSITY · PI MORENO, ALBERTO · 2012 to 2013
$484k
NCRR NIH HHS P51 RR000165NCRR NIH HHS RR00165NIAID NIH HHS P30 AI050409NIAID NIH HHS R21 AI094402NIAID NIH HHS R21-AI094402-01NIAID NIH HHS R21 AI095718NIAID NIH HHS R21-AI095718-01NIAID NIH HHS R56 AI103382NIAID NIH HHS R56-AI103382-01A1NIAID NIH HHS U19 AI109858NIAID NIH HHS U19-AI109858NIH HHS P51 OD011132
6 · The paper itself

Abstract

Plasmodium vivax is the most widespread species of Plasmodium, causing up to 50% of the malaria cases occurring outside sub-Saharan Africa. An effective vaccine is essential for successful control and potential eradication. A well-characterized vaccine candidate is the circumsporozoite protein (CSP). Preclinical and clinical trials have shown that both antibodies and cellular immune responses have been correlated with protection induced by immunization with CSP. On the basis of our reported approach of developing chimeric Plasmodium yoelii proteins to enhance protective efficacy, we designed PvRMC-CSP, a recombinant chimeric protein based on the P. vivax CSP (PvCSP). In this engineered protein, regions of the PvCSP predicted to contain human T cell epitopes were genetically fused to an immunodominant B cell epitope derived from the N-terminal region I and to repeat sequences representing the two types of PvCSP repeats. The chimeric protein was expressed in soluble form with high yield. As the immune response to PvCSP has been reported to be genetically restricted in the murine model, we tested the immunogenicity of PvRMC-CSP in groups of six inbred strains of mice. PvRMC-CSP was able to induce robust antibody responses in all the mouse strains tested. Synthetic peptides representing the allelic forms of the P. vivax CSP were also recognized to a similar extent regardless of the mouse strain. Furthermore, the immunization regimen induced high frequencies of multifunctional CD4(+) and CD8(+) PvRMC-CSP-specific T cells. The depth and breadth of the immune responses elicited suggest that immunization with PvRMC-CSP can circumvent the genetic restriction of the immune response to P. vivax CSP. Interestingly, PvRMC-CSP was also recognized by naturally acquired antibodies from individuals living in areas where malaria is endemic. These features make PvRMC-CSP a promising vaccine candidate for further development.

Indexed as

AnimalsAntibodies, ProtozoanBlotting, WesternChimeraDisease Models, AnimalEnzyme-Linked Immunosorbent AssayEpitopes, B-LymphocyteEpitopes, T-LymphocyteHumansMalaria VaccinesMalaria, VivaxMicePlasmodium vivaxProtein EngineeringProtozoan ProteinsRecombinant ProteinsAntibodies, Protozoancircumsporozoite protein, ProtozoanEpitopes, B-LymphocyteEpitopes, T-LymphocyteMalaria VaccinesProtozoan ProteinsRecombinant Proteins

Identifiers

PMID26169267
PMCPMC4534670
OpenAlexW1935379684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.